Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.
暂无分享,去创建一个
Philippe Broët | Bruno Lioure | Patrick Mayeux | C. Elie | J. Tamburini | V. Ugo | P. Broët | N. Ifrah | C. Lacombe | P. Cornillet‐Lefèbvre | P. Mayeux | D. Bouscary | Sophie Park | O. Blanchet | F. Dreyfus | Norbert Ifrah | Jerome Tamburini | François Dreyfus | B. Lioure | Catherine Lacombe | Didier Bouscary | Caroline Elie | Valérie Ugo | Nicolas Chapuis | Valérie Bardet | Sophie Park | Pascale Cornillet-Lefebvre | Odile Blanchet | Francis Witz | N. Chapuis | F. Witz | V. Bardet
[1] J. Tamburini,et al. Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutations , 2006, Leukemia.
[2] Steven M Kornblau,et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. , 2004, Blood.
[3] C. Billottet,et al. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. , 2006, Oncogene.
[4] C. Sawyers. Will kinase inhibitors have a dark side? , 2006, The New England journal of medicine.
[5] E. Solary,et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. , 2005, Blood.
[6] B Asselain,et al. A Semiparametric Approach for the Two‐Sample Comparison of Survival Times with Long‐Term Survivors , 2001, Biometrics.
[7] A. Khwaja,et al. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways , 2005, Leukemia.
[8] O. Bernard,et al. Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype , 2006, Leukemia.
[9] D Puthier,et al. High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis , 2001, Human mutation.
[10] M. Carroll,et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.
[11] H. Kaneko,et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.
[12] J. Cheong,et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable , 2003, Leukemia.
[13] E. Solary,et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .
[14] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[15] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[16] A. Toker,et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.
[17] J. Tamburini,et al. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. , 2006, Haematologica.